The United Kingdom and the United States have concluded a important trade agreement that will keep no duties on UK drug products being sold in the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase expenditure on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that tariffs on these key goods will be held at zero for a timeframe of three years.
This deal follows earlier statements to significantly raise import taxes on patented pharmaceutical products, with figures discussed up to 100%.
"This arrangement with the Britain bolsters the international landscape for cutting-edge drugs and establishes long-overdue balance to American-British medicine commerce," an announcement noted.
Economic Importance
Medicines represent one of the the United Kingdom's most significant export categories to the America, which is by far the largest market for major British pharmaceutical firms.
Export figures indicate that in the year prior to the third quarter, the UK shipped pharmaceutical products worth £11.1bn to the US. This figure made up nearly one-fifth of total UK exports in that span.
"This guarantee secures work, stimulates investment and paves the way for the UK to emerge as a worldwide center for medical research," a government official stated.
Key British Pledges
The deal involves several specific pledges from the UK:
- Price Threshold Increase: The UK will lift the price threshold at which it considers new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a goal to raise overall NHS spending on drugs from 0.3% of the national economy to 0.6% over the next decade.
- Payback Limit: The percentage drug companies must refund to the NHS to stay within budget will be restricted at fifteen percent. Last year, refunds exceeded 20%.
Industry Background
This agreement follows a ongoing row between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
The disagreement were heightened by arguments that American consumers were paying several times more for the equivalent treatments than people in the other developed nations.
Over the last 18 months, several major drug company projects in the UK have been delayed or abandoned, while multi-billion-dollar investments have been pledged toward US facilities.
One official publicly accepted that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the last ten years.
